Niemann Pick Disease Type C Npc — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for niemann pick disease type c npc . 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2037. Daily refresh.

1
Approved drugs
3
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Niemann Pick Disease Type C Npc

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Intrabio 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating niemann pick disease type c npc . Each bar = one year. Y-axis scaled to peak year (3 patents).

3
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aqneursa
LEVACETYLLEUCINE
 Intrabio 3 75 — 2037-04-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11400067 Aqneursa method of use 75 2037-04-19
12433862 Aqneursa method of use 75 2037-04-19
12433863 Aqneursa method of use 75 2037-04-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11400067 Aqneursa method of use 75 2037-04-19
12433862 Aqneursa method of use 75 2037-04-19
12433863 Aqneursa method of use 75 2037-04-19

Related